Clinical Trial Update: Reduction of Low-Density Lipoprotein Cholesterol (LDL-C) With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study [Phase 2]

View source ↗

Summary

Phase 2 trial update on PCSK9 inhibition showing reduction of LDL cholesterol in individuals with heterozygous familial hypercholesterolemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Familial Hypercholesterolemia

Drugs mentioned

• PCSK9 inhibitor (PCSK9 inhibitor)

Snippet

Sponsor: Amgen | Conditions: Hypercholesterolemia, Familial | Phase 2 | Status: COMPLETED | Results posted: 2015-09-29